SII, Bharat Biotech jointly communicate pledge towards smooth rollout of COVID-19 vaccines
Covaxin and Covishield in India: The Serum Institute of India and Bharat Biotech on Tuesday jointly communicated their pledge towards a smooth rollout of COVID-19 vaccines to India and the World.
Adar Poonawala and Krishna Ella, jointly on behalf of the two Companies, communicated their combined intent to develop manufacture, and supply the COVID-19 vaccines for India and globally.
Also Read | Here’s the difference between Bharat Biotech’s Covaxin and Serum Institute of India’s Covishield
They said the more important task in front of them is saving the lives and livelihoods of populations in India and the world.
Vaccines are a global public health good and they have the power to save lives and accelerate the return to economic normalcy at the earliest," they said.
Also Read | Cost of Covaxin may be a little higher: Bharat Biotech MD
"Now that two COVID-19 vaccines have been issued EUA (emergency use authorization) in India, the focus is on manufacturing, supply and distribution, such that populations that need it the most receive high quality, safe and efficacious vaccines," the joint statement added.
Both our Companies are fully engaged in this activity and consider it our duty to the nation and the world at large to ensure a smooth rollout of vaccines," the statement said, adding that "Each of our Companies continues their COVID-19 vaccines development activities as planned."
They further said "We are fully aware of the importance of vaccines for people and countries alike, we hereby communicate our joint pledge to provide global access for our COVID-19 vaccines."
-PTC News
